CD8A and colorectal carcinoma: In the pilot clinical trial of perioperative durvalumab combined with tremelimumab for treating resectable CRC liver metastases, the treatment induced activation of CD8+ and CD4+ T cells, and an increase in B-cell density was correlated with patients’ prolonged relapse-free survival (93).